Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on March 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). ATM facility doubled to $200M from $100M: Jefferies acting as sales agent at up to 3.0% commission on gross sales.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM facility doubled to $200M from $100M: Jefferies acting as sales agent at up to 3.0% commission on gross sales
- Zero shares sold under original $100M agreement (Aug 2024), so full $200M capacity is available
- New S-3 shelf (File No. 333-294272) filed and automatically effective March 13, 2026: dilution risk is immediate and ongoing
- ATM structure allows flexible, continuous equity issuance without a fixed offering price: common for cash-burn stage biotechs needing runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.